Featured Articles

Developing a Topical Adjunct to Injectable Procedures

By June 24, 2020July 1st, 2020No Comments

Dermatology News

Featured Article

“In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. “

Read Article Now

Developing a Topical Adjunct to Injectable Procedures

New JDD study reveals 81% of subjects applying a topical product had less bruising at day 2/3 compared to the bland moisturizer.

Injectable procedures have come to play an enormous part in everyday  aesthetic medical practice. Whether its use is directed at volumizing with fillers, decreasing volume using enzymes, skin-tightening using multi-needle approaches, or neuromuscular blockade, the injectable route is the means of delivery in all these cases, making injectable procedures the most common aesthetic procedure performed.

As with all procedures, expected and unexpected consequences may follow including bruising, swelling, discomfort, and the possibility of infection. This paper outlines the scientific process and validation of a product designed as an adjunct to injection therapy and the scientific deep dive needed to encompass both symptomatic and adjunctive purposes. On the symptomatic side, bruising, swelling, and pain were considered, while volumetric enhancement, regeneration, and anti-microbial/biofilm effects were desired outcomes from the adjunctive perspective.

Utilizing peptides and active agents aimed at reducing excess residual iron and stimulating macrophage absorption of red blood cells, we were able to achieve efficient resolution of bruising. In addition, peptides were included to stimulate collagen, elastin, and hyaluronic acid in synergy with the injectable. Anti-inflammatory, antimicrobial, and antibiofilm agents were added to aid in the safety profile of the injectable.

In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. Overall, 81% of subjects applying the study topical product had less bruising at day 2/3 compared to the bland moisturizer.

Read Article Now
JDD Article Referenced in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About A Review of the Role of C. Acnes and its Biofilm in Dandruff Pathogenesis

A Review of the Role of C. Acnes and its Biofilm in Dandruff Pathogenesis

| Featured Articles, Hair, Latest News, The Latest | No Comments
The Hidden Role of C. acnes in Dandruff: Beyond the Flakes Dandruff affects nearly 50% of the global population, yet its exact causes remain under ongoing investigation. While most clinicians…
Journal of Drugs in Dermatology JDD Article About Weight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study

Weight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study

| Featured Articles, Latest News, The Latest | No Comments
Isotretinoin Dosing in Adolescents: Does Weight Change Matter? Isotretinoin remains the gold standard for treating severe nodulocystic acne, with cumulative dosing of 120-150 mg/kg shown to balance safety and efficacy. Higher…

JDD in the News: Upadacitinib’s Potential Cardiovascular Effects 

| Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Upadacitinib may provide additional health benefits, including reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). That’s according to a May Journal of Drugs in Dermatology…

Leave a Reply